{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:02:31Z","timestamp":1790514151400,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":793,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1111\/jth.14935","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T10:18:06Z","timestamp":1598869086000},"page":"2126-2137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-6881","authenticated-orcid":false,"given":"St\u00e9phane","family":"Zuily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-390X","authenticated-orcid":false,"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2522-2705","authenticated-orcid":false,"given":"Scott C.","family":"Woller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-4873","authenticated-orcid":false,"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0559-5798","authenticated-orcid":false,"given":"Virginie","family":"Dufrost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-6793","authenticated-orcid":false,"given":"Denis","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-4970","authenticated-orcid":false,"given":"Caroline J.","family":"Dor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-6071","authenticated-orcid":false,"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-2579","authenticated-orcid":false,"given":"Katrien M.J.","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14935_bb0010","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"American College of Chest Physicians. Evidence\u2010based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14935_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence\u2010based recommendations for the prevention and long\u2010term management of thrombosis in antiphospholipid antibody\u2010positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz\u2010Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1111\/jth.14935_bb0020","doi-asserted-by":"crossref","unstructured":"Crowther M, Legault KJ, Garcia DA, et al. Antiphospholipid syndrome. Current Research Highlights and Clinical Insights. Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. Page 223\u2013233. Editor: Springer Nature. 2017.","DOI":"10.1007\/978-3-319-55442-6_11"},{"key":"10.1111\/jth.14935_bb0025","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jth.14935_bb0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1111\/jth.14935_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/dj4010005","article-title":"New Direct Oral Anticoagulants (DOAC) and Their Use Today","volume":"4","author":"Schwarb","year":"2016","journal-title":"Dentistry Journal"},{"key":"10.1111\/jth.14935_bb0040","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/jth.13481","article-title":"Subcommittees on Control of Anticoagulation and Lupus Anticoagulant\/Antiphospholipid Antibodies. Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH","volume":"14","author":"Tripodi","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0045","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high\u2010risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0050","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC). EMA\/PRAC\/219985\/2019. https:\/\/www.ema.europa.eu\/en\/documents\/prac\u2010recommendation\/prac\u2010recommendations\u2010signals\u2010adopted\u20108\u201011\u2010april\u20102019\u2010prac\u2010meeting_en.pdf. 2019;."},{"key":"10.1111\/jth.14935_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz726","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","author":"Konstantinides","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.14935_bb0060","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1111\/jth.14935_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/rth2.12287","article-title":"Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance.","volume":"4","author":"Fazili","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1111\/jth.14935_bb0070","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1538-7836.2012.04662.x","article-title":"SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH","volume":"10","author":"Baglin","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0075","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jth.12708","article-title":"Guidance, guidelines, and communications","volume":"12","author":"Douketis","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0080","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open\u2010label, phase 2\/3, non\u2010inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14935_bb0085","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE\u2010COVER(R)","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"key":"10.1111\/jth.14935_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1076029617729214","article-title":"Protocol modification of Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study","volume":"24","author":"Woller","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.14935_bb0095","first-page":"204","article-title":"Single\u2010arm pilot feasibility cohort Study of Rivaroxaban in antiphospholipid syndrome","volume":"2","author":"Legault","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi\u2010Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.14935_bb0105","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0961203319881200","article-title":"Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study","volume":"28","author":"Sato","year":"2019","journal-title":"Lupus"},{"key":"10.1111\/jth.14935_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0961203319889156","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study","volume":"29","author":"Malec","year":"2019","journal-title":"Lupus"},{"key":"10.1111\/jth.14935_bb0115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient\u2010level data meta\u2010analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1111\/jth.14935_bb0120","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.clinthera.2019.06.015","article-title":"Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta\u2010analysis","volume":"41","author":"Sanchez\u2010Redondo","year":"2019","journal-title":"Clin Ther"},{"key":"10.1111\/jth.14935_bb0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta\u2010analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0130","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios AEMPS ANTICOAGULANTES ORALES DIRECTOS*: NO RECOMENDADOS EN PACIENTES CON S\u00cdNDROME ANTIFOSFOL\u00cdPIDO Y ANTECEDENTES DE TROMBOSIS https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2019\/docs\/NI_MUH_FV\u20108\u20102019\u2010anticoagulantes\u2010orales.pdf."},{"key":"10.1111\/jth.14935_bb0135","unstructured":"UK Medicines and Healthcare products (MHRA) regulatory Agency on the Department of Health; Direct\u2010acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome advice to healthcare professionals: https:\/\/www.gov.uk\/drug\u2010safety\u2010update."},{"key":"10.1111\/jth.14935_bb0140","unstructured":"ANSM: Lettre aux professionnels de sant\u00e9. https:\/\/ansm.sante.fr\/S\u2010informer\/Informations\u2010de\u2010securite\u2010Lettres\u2010aux\u2010professionnels\u2010de\u2010sante\/Anticoagulants\u2010Oraux\u2010Directs\u2010AODs\u2010apixaban\u2010Eliquis\u2010R\u2010rivaroxaban\u2010Xarelto\u2010R\u2010dabigatran\u2010Pradaxa\u2010R\u2010et\u2010edoxaban\u2010Lixiana\u2010R\u2010Roteas\u2010R\u2010non\u2010recommandes\u2010chez\u2010les\u2010patients\u2010presentant\u2010un\u2010Syndrome\u2010des\u2010Antiphospholipides\u2010SAPL\u2010Lettre\u2010aux\u2010professionnels\u2010de\u2010sante."},{"key":"10.1111\/jth.14935_bb0145","unstructured":"Safety\u2010related D.Labeling Changes (SrLC). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/index.cfm?event=searchdetail.page&DrugNameID=238."},{"key":"10.1111\/jth.14935_bb0150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rmr.2019.01.003","article-title":"Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version","volume":"36","author":"Sanchez","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1111\/jth.14935_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1024\/0301-1526\/a000815","article-title":"Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies","volume":"48","author":"Bauersachs","year":"2019","journal-title":"Vasa"},{"key":"10.1111\/jth.14935_bb0160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta\u2010analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1111\/jth.14935_bb0165","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.14935_bb0170","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO\u2010APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.14935_bb0180","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jth.14935_bb0185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11926-017-0687-z","article-title":"Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a thrombophilia or a vasculopathy?","volume":"19","author":"Siddique","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/jth.14935_bb0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14935_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.111.028522","article-title":"Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta\u2010analysis of echocardiographic studies","volume":"124","author":"Zuily","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.14935_bb0200","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2017.04.003","article-title":"Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta\u2010analysis","volume":"6","author":"Zuily","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1111\/jth.14935_bb0205","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"Garcia","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0210","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","article-title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","volume":"131","author":"Kearon","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14935_bb0220","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0225","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"Gebhart","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0230","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high\u2010risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.14935_bb0235","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1111\/jth.14935_bb0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jth.14720","article-title":"Prevalence of confirmed antiphospholipid syndrome in 18\u201350 years unselected patients with first unprovoked venous thromboembolism","volume":"18","author":"Miranda","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0245","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The Epidemiology of Antiphospholipid Syndrome: A Population\u2010Based Study","volume":"71","author":"Duarte\u2010Garc\u00eda","year":"2019","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"10.1111\/jth.14935_bb0250","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0255","unstructured":"Zuily S, Dufrost V, Devreese K.International Registry of Thrombotic APS patients Treated With Direct Oral Anticoagulants. https:\/\/www.isth.org\/members\/group.aspx?id=100353."},{"key":"10.1111\/jth.14935_bb0260","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"de Werf F, RE\u2010ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14935_bb0265","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2013an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14935_bb0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF\u2010TIMI 48 Trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jth.14935_bb0275","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO\u2010APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14935","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14935","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622016476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622016476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:31:09Z","timestamp":1761535869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622016476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1538783622016476"],"URL":"https:\/\/doi.org\/10.1111\/jth.14935","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}